FDA opens door to feedback on ‘unclear’ national priority voucher pathway
The US Food and Drug Administration (FDA) will convene a public hearing intended to obtain feedback on its Commissioner's National …
Post
-
-
Cognito Therapeutics and Ochsner partner for new brain health approaches
US-based neurotechnology company Cognito Therapeutics has collaborated with Ochsner Health to establish the Brain Health Collaboratory, aiming to advance new …
-
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
Daiichi Sankyo has entered a strategic collaboration with Tempus AI to expedite the clinical development and differentiation of an antibody …
-
The Most Favored Nation Policy: early insights into Europe’s response
On 12 May 2025, US President Donald Trump signed an executive order directing the US Department of Health and Human …
-
UCB banks on Georgia for $2bn biologics manufacturing facility
UCB has chosen Georgia as the home for its new biologics manufacturing facility, cementing its legacy in the state and …
-
Improving early detection and treatment of liver cancer
Outcomes for liver cancer patients are highly stage dependent. Interventions designed to be curative, such as minimally invasive ablation, tumour …
-
MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement
MSD will buy cancer specialist Terns Pharmaceuticals in a deal worth $6.7bn, as the drugmaker continues its string of multibillion-dollar …
-
Researchers become scientific tastemakers by handing more R&D to autonomous labs
Pharmaceutical R&D is falling increasingly to artificial intelligence (AI)-guided autonomous laboratories, and the people behind them say the role of …
-
Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis
Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause …
-
MSD and Quotient collaborate on IBD drug targets
Merck & Co (MSD) has signed a multi-year research collaboration with Quotient Therapeutics to discover new drug targets for inflammatory …
-
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition
On 23 February, Gilead Sciences announced its $7.8bn acquisition of Arcellx, primarily to secure rights to anitocabtagene autoleucel (anito-cel), an …
-
Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout
Gilead Sciences is set to acquire Ouro Medicines for $2.2bn, marking the company’s first move into the T-cell engager (TCE) …
-
Monash University and ClinChoice partner on new therapies development
Australia-based Monash University and ClinChoice have announced a strategic partnership to accelerate clinical development of new therapies. This collaboration is also …
-
Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody
Sanofi has signed an exclusive global licence agreement with Kali Therapeutics for KT501, a new tri-specific antibody for B cell-mediated …
-
Clinical trials: Are data managers ready for AI in EDC?
AI in clinical trials has the potential to offer faster insights, greater efficiency, and improved data quality. Nowhere is this …
